Amgen Inc., Cytokinetics Inc. and Servier said they would continue
the GALACTIC-HF Phase 3 heart failure trial following a planned interim
analysis.
The companies said the Data Monitoring Committee recommended the
Phase 3 clinical trial of omecamtiv mecarbil in patients with heart
failure continue without changes.
Topline results are expected in the fourth quarter of 2020.
GALACTIC-HF completed enrollment of more than 8,200 patients in 35
countries who were either hospitalized at the time of enrollment for a
primary reason of heart failure, or had a hospitalization or admission
to an emergency room for heart failure within one year prior to
screening.
Omecamtiv mecarbil is being developed by Amgen in collaboration with
Cytokinetics, with funding and strategic support from Servier.
https://www.marketscreener.com/AMGEN-INC-4847/news/Amgen-Cytokinetics-to-Continue-Phase-3-Heart-Failure-Trial-30067294/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.